Blue Cross of Idaho Logo

Express Sign-on

Thank you for registering with Blue Cross of Idaho

If you are an Individual or Family Member under age 65, please register here.

If you are an Medicare or Medicare Supplement member, please register here.

New Options for Affordable Health Insurance


MP 2.01.82 Bioimpendance Devices for Detection of Lymphedema

Medical Policy    
Original Policy Date
Last Review Status/Date
Reviewed with Literature search/11:2012
  Return to Medical Policy Index


Our medical policies are designed for informational purposes only and are not an authorization, or an explanation of benefits, or a contract. Receipt of benefits is subject to satisfaction of all terms and conditions of the coverage. Medical technology is constantly changing, and we reserve the right to review and update our policies periodically.


Secondary lymphedema may develop following surgery for breast cancer. Bioelectrical impedance is being studied as a diagnostic test for lymphedema, particularly for subclinical disease.

Secondary lymphedema of the upper extremity may develop following surgical treatment for breast cancer; it has been reported in approximately 25% to 50% of women following mastectomy. This can be a chronic, disfiguring condition. It results from lymphatic dysfunction or disruption and can be difficult to accurately diagnose and manage. One challenge is identifying the presence of clinically significant limb swelling through simple noninvasive methods. Many techniques have been used for documenting lymphedema including measuring differences in limb volume (volume displacement) and limb circumference. A number of newer techniques are being evaluated, including bioimpedance with use of bioimpedance spectroscopy (BIS) analysis, which uses resistance to electrical current in comparing the composition of fluid compartments. BIS is based on the theory that the amount of opposition to flow of electric current (impedance) through the body is inversely proportional to the volume of fluid in the tissue. In lymphedema, with the accumulation of excess interstitial fluid, tissue impedance decreases.

The detection of subclinical lymphedema, that is, the early detection of lymphedema before clinical symptoms become apparent, is another area of study. Detection of subclinical lymphedema (referred to as Stage 0 lymphedema) is problematic. Subclinical disease may exist for months or years before overt edema is noted. This approach generally involves comparison of preoperative (i.e. baseline) with postoperative measurements, since existing differences between upper extremities (like the effects of a dominant extremity) may obscure early, subtle differences resulting from the initial accumulation of fluid. Bioimpedance has been proposed as one diagnostic test for this condition. Those who support this approach to diagnose subclinical disease believe that early treatment of subclinical lymphedema should result in less severe chronic disease.

Regulatory Status

One of the devices is the ImpediMed L-Dex™ U400 cleared for marketing by the U.S. Food and Drug Administration (FDA) through the 510(k) process in 2007 (1) and in 2008. (2) According to the FDA letter, the device is “to aid in the clinical assessment of unilateral lymphedema of the arm in women. The device is not intended to diagnose or predict lymphedema of an extremity.”

Related Policies



1.01.18 Pneumatic Compression Pumps for Treatment of Lymphedema

2.02.17 End Diastolic Pneumatic Compression Boot for the Treatment of Peripheral Vascular Disease or Lymphedema 


Devices using bioimpedance (bioelectrical impedance spectroscopy) are considered investigational for use in the diagnosis, surveillance, or treatment of patients with lymphedema, including use in subclinical secondary lymphedema..

Policy Guidelines

Effective in 2011, there is a category III CPT code for bioelectrical impedance testing:

0239T: Bioimpedance spectroscopy (BIS), measuring 100 frequencies or greater, direct measurement of extracellular fluid differences between the limbs.

Prior to the creation of the category III code, this service was likely being coded using CPT code 38999 – unlisted procedure, hemic or lymphatic system.

Benefit Application 

BlueCard/National Account Issues

State or federal mandates (e.g., FEP) may dictate that all FDA-approved devices, drugs, or biologics may not be considered investigational and thus these devices may be assessed only on the basis of their medical necessity.


Assessment of a diagnostic technology typically focuses on 3 parameters: 1) technical performance; 2) diagnostic performance (sensitivity, specificity, and positive and negative predictive value) in appropriate populations of patients; and 3) demonstration that the diagnostic information can be used to improve patient outcomes (clinical utility). While in some cases, tests can be adequately evaluated using technical and diagnostic performance, when a test identifies a new or different group of patients with a disease, randomized controlled trials (RCTs) are needed to demonstrate impact of the test on the net health outcome.

Literature Review

When the policy was created, a literature search was conducted using MEDLINE through January 2010 to identify relevant studies. The policy was updated regularly with MEDLINE searches, most recently for the period September 2011 through September 2012.

Technical performance

Technical performance of a device is typically assessed with 2 types of studies, those that compare test measurements with a gold standard and those that compare results taken with the same device on different occasions (test-retest). While there is no absolute gold standard for diagnosis of lymphedema, the de facto gold standards are limb volume and/or limb circumference.

A 2010 publication by Czerniec and colleagues reported on measurement of lymphedema in a small group of patients, 33 with lymphedema and 18 without. (3) This study was to determine the relationship between physical methods of measuring lymphedema and self-reported swelling. Measurement techniques included self-report, bioimpedance spectroscopy (BIS), perometer, and the truncated cone method. The authors noted that the physical measurement tools were highly reliable with high concordance (0.89 to 0.99, respectively). In this study, self-report correlated moderately with physical measurements (0.65 to 0.71, respectively) and was moderately reliable. The authors concluded that lymphedema assessment methods are concordant and reliable but not interchangeable.

In a U.S.-based study published in 2007, Warren et al. evaluated 15 patients with upper- or lower-extremity secondary lymphedema documented by lymphoscintigraphy, along with 7 healthy controls using BIS analysis. (4) In addition, both the affected and unaffected limbs in lymphedema patients were evaluated so patients also served as their own controls. According to BIS in the lymphedema patients, the average ratio of current flow of the affected limb to the unaffected limb (the impedance ratio) was 0.9 (range: 0.67 to 1.01). In the control group, the average impedance ratio was 0.99 (range: 0.95 to 1.02). Lower impedance ratio values correlated with higher levels of accumulated fluid.

Diagnostic performance

A technology assessment on the diagnosis and treatment of secondary lymphedema, performed under contract from Agency for Healthcare Research and Quality (AHRQ) by the McMaster University Evidence-based Practice Center, was released in May 2010. (5) The assessment identified 8 studies that reported the sensitivity and specificity of tests to diagnose secondary lymphedema. Two of these studies evaluated bioimpedance devices, Cornish et al. 2001 (6) and Hayes et al. 2008, (7) and are briefly described below:

Cornish and colleagues in Australia followed 102 patients after treatment for breast cancer. (6) Twenty patients developed lymphedema in the 24 months’ follow-up period, and in these 20 cases, multi-frequency bioelectrical impedance analysis (MFBIA) predicted the onset of the condition up to 10 months before the condition was diagnosed clinically. Estimates of the sensitivity and specificity were both approximately 100%. At the time of detection by MFBIA, only one of the patients had a positive test result from the total limb volume determined from the circumferential measures.

In another study from Australia, Hayes and colleagues noted that the point prevalence of lymphedema varies according to the approach to diagnosis. (7) In this study, lymphedema status was assessed at 3-month intervals between 6 and 18 months post-surgery in a sample of Australian women with unilateral, invasive breast cancer, using 3 methods: bioimpedance spectroscopy, difference between sum of arm circumferences (SOAC), and self-report. Depending on the method, point prevalence ranged between 8% to 28%, with 1 in 5 to 2 in 5 women experiencing lymphedema at some point in time. According to the technology assessment, the sensitivity and specificity of bioimpedance compared to SOAC was 42% and 88%, respectively and the sensitivity and specificity of bioimpedance compared to self-report was 61% and 59%, respectively.

More recently, in 2011, Smoot and colleagues reported on diagnostic test characteristics including sensitivity, specificity, and area under the receiver-operating-characteristic (ROC) curve for a number of tests used in the diagnosis of breast cancer-related lymphedema. (8) For this study, a total of 141 women were classified as having (n=70) or not having (n=71) breast cancer-related lymphedema (BCRL) based on past diagnosis by a healthcare provider. Areas under the curve for a number of bioimpedance measures and volume measures were in the 0.79 to 0.88 range, with overlap in confidence intervals. Given questions about the standard used for diagnosis and apparent lack of patients with subclinical lymphedema, this study provides little new information. Finally, in a study from Australia, Ward and colleagues concluded that the impedance ratio thresholds for early detection of lymphedema remain suitable for clinical use with present-day analyzers. (9)

In 2012, Vicini and colleagues published a retrospective analysis of data from 64 women who underwent surgery for breast cancer and had pre-surgical and post-surgical measurements of bioelectrical impedance assessment using an ImpediMed L-Dex device. (10) Post-surgical measurement occurred within 90 days of surgery and before radiation therapy or chemotherapy. Change in the lymphedema index ratios (LIR) pre- and post-procedure was compared. LIR was defined as the difference in volume or impedance between the affected and non-affected arm. The authors did not discuss a reference standard test. For the group as a whole, median LIR was 0.5 at baseline and the median change in LIR after surgery was 1.1. The authors noted that, although differences between groups were not statistically significant, there appeared to be a greater change in LIR pre- and post-surgery in patients who received more aggressive treatment e.g., larger numbers of nodes removed or dissection of axillary nodes compared to sentinel node only. The study did not include a reference standard test and did not report sensitivity and specificity of bioelectrical impedance analysis.

Clinical utility

No randomized controlled trials were identified that compared health outcomes in patients who were managed with and without the use of bioimpedance devices. A related question is whether early detection and treatment of subclinical lymphedema, using a bioimpedance device or another detection method, improves health outcomes. The literature on treatment shows variability among studies regarding response to therapy for secondary lymphedema. Some studies found that mild disease was more responsive to treatment; other studies did not. Similarly, when duration of symptoms was reported, there was no clear relationship between duration of the edema and response to treatment. A study by Stout Gergich and colleagues, published in 2008, is frequently cited as support for the early detection and treatment of subclinical lymphedema. (11) In this study, lymphedema was identified in 43 of 196 women who participated in a prospective breast cancer morbidity trial. Limb volume was measured preoperatively and at 3-month intervals after surgery using perimetry (another evolving technique). If an increase of greater than 3% in upper limb volume developed compared with the preoperative volume, a diagnosis of lymphedema was made and a compression garment intervention was prescribed for 4 weeks. Statistical analysis was a repeated-measures analysis of variance by time and limb (p<0.001) comparing the lymphedema cohort with an age-matched control group. In this study, the time to onset of lymphedema averaged 6.9 months postoperatively. The mean (+/-standard deviation [SD]) affected limb volume increase was 83 mL (+/-119 mL) at lymphedema onset compared with baseline. Of note, clinical lymphedema is generally felt to be apparent when 200 mL of fluid accumulates. After the intervention, a statistically significant mean 48 mL (+/-103 mL) volume decrease was realized. The mean duration of the intervention was 4.4 weeks. Volume reduction was maintained at an average follow-up of 4.8 months after the intervention. The authors concluded that a short trial of compression garments effectively treated subclinical lymphedema. This study does not answer the key question; that is, whether net health outcome was improved by early intervention. In addition, the role of novel diagnostic testing compared to the use of the de facto gold standard tests (limb volume or circumference) also needs to be evaluated.

A study on a protocol to prevent lymphedema in women with breast cancer and axillary node dissection was published by Boccardo and colleagues in 2009. (12) The study included 55 women. The preventive group had volumetric (arm volume) measurements performed preoperatively and at 1, 3, 5, 12, and 24 months postoperatively. The protocol for this group included principles to minimize lymphedema risk, lymphoscintigraphy preoperatively and at 6 months postoperatively, and early management of the condition once identified. Clinically significant lymphedema was an increase of at least 200 mL from the preoperative difference between the two arms. Assessments at 2 years were completed for 89% of the 55 women who were randomly assigned to either preventive group or control. Of the 49 who were measured at 2 years, 10 (21%) were identified with secondary lymphedema with an incidence of 8% in the preventive group and 33% in controls. The authors noted that these prophylactic strategies appear to reduce the development of secondary lymphedema and alter its progression. This is a relatively small study, and the various interventions used may have each played a role in the outcome for this study. The study did not include use of bioimpedance devices.

Clinical Input Received through Physician Specialty Societies and Academic Medical Centers

Clinical input on this policy was received from 2 academic medical centers and 2 specialty societies in 2011. Three out of four reviewers agreed that bioimpedance devices are considered investigational for diagnosis, surveillance, and treatment of patients with lymphedema. One specialty society noted that they support further research into effectiveness of this technology and recommend reimbursement in the context of relevant clinical trials. The fourth reviewer, who was from an academic medical center, thought that the literature cited in the policy was adequate but drew different conclusions. In particular, the reviewer thought that use of the technology is a reasonable alternative, especially in situations in which minor lymphedema can have a large impact on a patient.


There is minimal information about the technical and diagnostic performance of bioimpedance testing in the diagnosis (surveillance) of secondary lymphedema; especially for subclinical disease. In addition, there are no data from comparative clinical trials that demonstrate the impact of this test (bioimpedance) on clinical outcomes (clinical utility). Thus, based on the current scientific evidence and because the impact on net health outcome is not known, use of this testing in the diagnosis or management of patients with known or suspected lymphedema, or to detect subclinical lymphedema, is considered investigational.

Medicare National Coverage

There is no national coverage determination on bioimpedance devices.


  1. FDA 510(k) summary: ImpediMed IMP XCA ExtraCellular Fluid Analysis. Available online at: Last accessed October, 2012.
  2. FDA 510(k) summary: ImpediMed L-Dex U400 BIS Extra Cellular Fluid Analysis. Available online at: Last accessed October, 2012.
  3. Czerniec SA, Ward LC, Refshauge KM et al. Assessment of breast cancer-related arm lymphedema-comparison of physical measurement methods and self-report. Cancer Invest 2010; 28(1):54-62.
  4. Warren AG, Janz BA, Slavin SA et al. The use of bioimpedance analysis to evaluate lymphedema. Ann Plast Surg 2007; 58(5):541-3.
  5. Oremus M, Walker K, Dayes I et al. Technology Assessment: Diagnosis and treatment of secondary lymphedema. 2010; Project ID:LYMT0908. Available online at: Last accessed October, 2012.
  6. Cornish BH, Chapman M, Hirst C et al. Early diagnosis of lymphedema using multiple frequency bioimpedance. Lymphology 2001; 34(1):2-11.
  7. Hayes S, Janda M, Cornish B et al. Lymphedema secondary to breast cancer: how choice of measure influences diagnosis, prevalence, and identifiable risk factors. Lymphology 2008; 41(1):18-28.
  8. Smoot BJ, Wong JF, Dodd MJ. Comparison of diagnostic accuracy of clinical measures of breast cancer-related lymphedema: area under the curve. Arch Phys Med Rehabil 2011; 92(4):603-10.
  9. Ward LC, Dylke E, Czerniec S et al. Confirmation of the reference impedance ratios used for assessment of breast cancer-related lymphedema by bioelectrical impedance spectroscopy. Lymphat Res Biol 2011; 9(1):47-51.
  10. Vicini F, Shah C, Lyden M et al. Bioelectrical impedance for detecting and monitoring patients for the development of upper limb lymphedema in the clinic. Clin Breast Cancer 2012; 12(2):133-7.
  11. Stout Gergich NL, Pfalzer LA, McGarvey C et al. Preoperative assessment enables the early diagnosis and successful treatment of lymphedema. Cancer 2008; 112(12):2809-19.
  12. Boccardo FM, Ansaldi F, Bellini C et al. Prospective evaluation of a prevention protocol for lymphedema following surgery for breast cancer. Lymphology 2009; 42(1):1-9.




CPT  0239T Bioimpedance spectroscopy (BIS), measuring 100 frequencies or greater, direct measurement of extracellular fluid differences between the limbs (new code effective 1/1/11)
ICD-9 Diagnosis    Investigational for all diagnoses
ICD-10-CM (effective 10/1/14)   investigational for all diagnoses
  I97.2 Postmastectomy lymphedema syndrome
  Z90.10-Z90.13 Acquired absence of breast and nipple code range
ICD-10-PCS (effective 10/1/14)   ICD-10-PCS codes are only used for inpatient services. There is no specific ICD-10-PCS code for this testing.


Bioelectrical impedance testing
Bioimpedance spectroscopy
Lymphedema, bioimpedance testing

Policy History

Date Action Reason
04/14/11 New policy; add to Medicine section New policy; considered investigational
11/10/11 Replace policy

Policy updated with literature search, clinical input reviewed, policy statement unchanged 

11/08/12 Replace Policy Policy updated with literature search. Policy statement unchanged. Rationale substantially rewritten. Reference 10 added; other references renumbered or removed.